August 14, 2025 – Talk Bio

Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

1 week ago talkbio0Tagged CDC7 protein, human, clinical trial halt, drug safety, Inhibitor, leukemia, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, patient deaths, Schrödinger, SGR-2921

Schrödinger; SGR-2921; leukaemia; acute myeloid leukaemia (AML); myelodysplastic syndromes (MDS); CDC7 inhibitor; clinical trial halt; patient deaths; drug safety

US to Stockpile Critical Drug Ingredients Under Latest Trump Executive Order

1 week ago talkbio0Tagged ASPR, domestic manufacturing, drug ingredients, essential medicines, executive order, National Security, Pharmaceutical Ingredients Reserve, Pharmaceutical Supply Chain, strategic, Transplant Registry Unified Management Program

Trump; Executive Order; drug ingredients; pharmaceutical supply chain; Strategic Active Pharmaceutical Ingredients Reserve; ASPR; domestic manufacturing; national security; essential medicines

CytomX Continues Phase I ADC Study After Patient Death

1 week ago talkbio0Tagged ADC, Clinical Trials, Colorectal Carcinoma, CX-2051, CytomX, Kidney Failure, Acute, Patient Death, Phase I, Safety, therapeutic autologous dendritic cells, United States Food and Drug Administration

CytomX; CX-2051; Phase I; ADC; colorectal cancer; patient death; acute kidney injury; clinical trial; safety; FDA; trial continuation

Eli Lilly and Superluminal Ink $1.3B Pact Targeting GPCRs in Obesity, Cardiometabolic Diseases

1 week ago talkbio0Tagged Aortic Valve Insufficiency, cardiometabolic diseases, Eli, Eli Lilly, equity, GPCRs, Investments, MC4R, MC4R protein, human, milestones, Obesity, Partnership, Superluminal Medicines

Eli Lilly; Superluminal Medicines; GPCRs; obesity drugs; cardiometabolic diseases; AI drug discovery; MC4R; partnership; milestones; equity investment

Sarepta Sells $174 Million Stake in Arrowhead to Fund Milestone Payment Amid Cash Crunch

1 week ago talkbio0Tagged Arrowhead, Cash Crunch, Collaboration, milestone payment, Myotonic Dystrophy, private block trade, RNA Interference, SRP-1003, stake sale

Sarepta Therapeutics; Arrowhead Pharmaceuticals; cash crunch; stake sale; milestone payment; RNAi collaboration; SRP-1003; myotonic dystrophy; private block trade

NIH and HHS Cancel Major mRNA Vaccine Research Funding, Citing Lack of Public Trust

1 week ago talkbio0Tagged BARDA, COVID19 (disease), grant cancellation, Jay Bhattacharya, mRNA Vaccine, NIH Mouse, public trust, research funding, RFK Jr., Vaccination Hesitancy

NIH; mRNA vaccine; public trust; research funding; BARDA; COVID-19; vaccine hesitancy; RFK Jr.; Jay Bhattacharya; grant cancellation

Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan

1 week ago talkbio0Tagged cost-cutting, Keytruda, layoffs, Merck & Co., New Jersey, Pharma Industry, restructuring, WARN notice

Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice

Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced

1 week ago talkbio0Tagged cardiometabolic health, Discontinuation (procedure), Glucagon-Like Peptide 1, iMTP, Inhibitor, Obesity, Phase 2 Clinical Trials, postprandial, RDX-002, Response process, Triglycerides, weight regain

Response Pharmaceuticals; RDX-002; GLP-1 discontinuation; weight regain; obesity; Phase II clinical trial; postprandial triglycerides; cardiometabolic health; iMTP inhibitor

Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success

1 week ago talkbio0Tagged Biological Science Disciplines, Early-stage, Hatteras, Hatteras Opportunity Fund I, Hatteras Venture Fund VII, HistoSonics exit, medtech, Partner in relationship, startups, venture capital

Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I